New trial tests kremezin to stop kidney disease from becoming chronic
NCT ID NCT07182422
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests whether adding Kremezin (AST-120) to standard care can help people with acute kidney disease recover better by lowering harmful toxins in the blood. About 100 adults aged 18-80 with moderate kidney injury will take Kremezin or a placebo for 180 days. The goal is to see if this treatment can prevent long-term kidney damage and reduce the risk of heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY (AKI) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital, Taoyuan, Taiwan
RECRUITINGTaoyuan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.